Assesment of human epidermal growth factor receptor 2 status is a key factor prompting definitive treatment decisions that help in reducing mortality rates associated with breast cancer. In this article, highly sensitive and low-cost impedimetric immunosensor using single-chain fragment variable antibody fragments was developed for quantitative detection of human epidermal growth factor receptor 2 from serum employing gold nanoparticle-modified disposable screen-printed carbon electrodes. The gold nanoparticles facilitate fast electron transfer and offer a biocompatible surface for immobilization of small antibody fragments in an oriented manner, resulting in improved antigen binding efficiency. The single-chain fragment variable antibody fragment-modified screen printed immunosensor exhibits wide dynamic range of 0.01-100 ng mL and detection limit of 0.01 ng mL. The advantages offered by this platform in terms of high sensitivity, broad dynamic range and low-cost demonstrates great potential for improved monitoring of human epidermal growth factor receptor 2 levels for the management of breast and other cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bios.2018.01.056DOI Listing

Publication Analysis

Top Keywords

human epidermal
12
epidermal growth
12
growth factor
12
factor receptor
12
impedimetric immunosensor
8
single-chain fragment
8
fragment variable
8
variable antibody
8
antibody fragments
8
dynamic range
8

Similar Publications

Background: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis, necessitating the investigation of novel treatments and targets. This study evaluated JNJ-70218902 (JNJ-902), a T-cell redirector targeting transmembrane protein with epidermal growth factor-like and 2 follistatin-like domains 2 (TMEFF2) and cluster of differentiation 3, in mCRPC.

Patients And Methods: Patients who had measurable/evaluable mCRPC after at least one novel androgen receptor-targeted therapy or chemotherapy were eligible.

View Article and Find Full Text PDF

Purpose: To study the association between clinicopathologic characteristics of ductal carcinoma in situ (DCIS) and risk of subsequent invasive breast cancer (IBC).

Methods: We conducted a case-control study nested in a multicenter, population-based cohort of 8175 women aged ≥ 18 years with DCIS diagnosed between 1987 and 2016 and followed for a median duration of 83 months. Cases (n = 497) were women with a first diagnosis of DCIS who developed a subsequent IBC ≥ 6 months later; controls (2/case; n = 959) were matched to cases on age at and calendar year of DCIS diagnosis.

View Article and Find Full Text PDF

Background  Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder with diverse clinical presentations, among which hematological abnormalities often serve as early and critical indicators of disease. These manifestations, including anemia, leukopenia, lymphopenia, and thrombocytopenia, correlate with disease activity and provide essential diagnostic insights, particularly in resource-limited settings where access to advanced diagnostic tools may be constrained. This study emphasizes the significance of hematological findings that frequently appear at the initial presentation of SLE.

View Article and Find Full Text PDF

[The current treatment status and future of antibody drug conjugates in HER-2-alteration non-small cell lung cancer].

Zhonghua Zhong Liu Za Zhi

January 2025

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100021, China.

Non-small cell lung cancer(NSCLC) is one of the major histopathological types of lung cancer, accounting for about 85 percent of all lung cancers. The human epidermal growth factor receptor 2 (HER-2) alteration in NSCLC include gene mutations, gene amplifications, and protein overexpression, and is one of the important driving target. Currently, the treatment options for HER-2 altered NSCLC are still relatively limited, and more effective drugs are urgently needed.

View Article and Find Full Text PDF

Effect of amniotic fluid on hair follicle growth.

J Dermatolog Treat

December 2025

Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey.

Human amniotic fluid stem cells (hAFSCs) have shown significant regenerative potential in treating hair loss, wound healing, and tissue repair. This study aims to evaluate the effects of human amniotic fluid (hAF) on hair follicle (HF) regeneration and immune system modulation. The hAF used was pooled, acellular, and gamma-irradiated to standardize its contents and enhance its stability.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!